enGene Therapeutics Inc. (ENGN)
| Market Cap | 122.30M -76.5% |
| Revenue (ttm) | n/a |
| Net Income | -130.36M |
| EPS | -2.02 |
| Shares Out | 67.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 665,264 |
| Open | 1.850 |
| Previous Close | 1.850 |
| Day's Range | 1.775 - 1.889 |
| 52-Week Range | 1.400 - 12.250 |
| Beta | -0.24 |
| Analysts | Buy |
| Price Target | 4.29 (+134.85%) |
| Est. Earnings | Dec 21, 2026 |
About ENGN
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for ENGN stock is "Buy." The 12-month stock price target is $4.29, which is an increase of 134.85% from the latest price.
News
enGene Therapeutics Transcript: Jefferies Global Healthcare Conference
The pivotal dataset supports a planned BLA filing by year-end 2026, with FDA acceptance expected in early 2027 and approval targeted by year-end 2027. Updated durability measures improved, while a surfactant cohort and $246 million cash support upcoming milestones.
enGene Therapeutics Transcript: UBS Global Biopharma Conference 2026
Detalimogene’s updated LEGEND results showed 56% complete response and improving durability, alongside strong reported tolerability. Filing is planned by year-end 2026, with approval expected in 2027; a surfactant-cohort update is planned for mid-2027.
Leerink upgrades enGene to Outperform as worst-case scenario off the table
As previously reported, Leerink analyst Lili Nsongo upgraded enGene (ENGN) to Outperform from Market Perform with a price target of $5, up from $2, following the company’s updated LEGEND data…
enGene upgraded to Outperform from Market Perform at Leerink
Leerink analyst Lili Nsongo upgraded enGene (ENGN) to Outperform from Market Perform with a $5 price target
Piper Sandler upgraded enGene to Overweight on updated LEGEND data
As previously reported, Piper Sandler upgraded enGene (ENGN) to Overweight from Neutral with a $4 price target following an update to detalimogene data in which efficacy measures improved across the…
enGene upgraded to Overweight from Neutral at Piper Sandler
Piper Sandler upgraded enGene (ENGN) to Overweight from Neutral with an unchanged price target of $4.
enGene upgraded to Overweight from Equal Weight at Wells Fargo
Wells Fargo analyst Yanan Zhu upgraded enGene (ENGN) to Overweight from Equal Weight with a price target of $6, up from $2. The firm has increased confidence in detalimogene’s regulatory…
enGene Therapeutics Transcript: Study update
LEGEND cohort one reported a 56% anytime CR rate, with 12-month response durability improving to 43% and a 24% 12-month landmark CR rate. FDA discussions supported starting a BLA filing before year-end 2026, targeting potential 2027 approval.
enGene Therapeutics Press release: Study update
enGene Therapeutics issued a press release on November 11, 2026, disclosing material business information to investors.
enGene Therapeutics Slides: Study update
enGene Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on November 11, 2026.
enGene to initiate BLA submission for Detalimogene
enGene (ENGN) Therapeutics “announced updated results from the pivotal Cohort 1 of its ongoing, Phase 2 LEGEND trial of detalimogene voraplasmid (also known as detalimogene). Data from Cohort 1, which...
enGene names Goluboff CMO, Duncan CLAO
enGene (ENGN) Therapeutics announced the appointments of Erik T. Goluboff, MD, MBA as Chief Medical Officer and Jason Duncan as Chief Legal and Administrative Officer, effective November 9, 2026. enGe...
enGene to Initiate a BLA Submission for Detalimogene by Year End and Reports New Data from LEGEND Trial Pivotal Cohort 1 in BCG-Unresponsive NMIBC
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced updated results from the ...
enGene Appoints Key Executives in Anticipation of Upcoming Regulatory and Commercial Milestones
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN) (“enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced the appointments of Erik...
enGene to Participate in Upcoming Investor Conferences
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced that management will parti...
enGene Therapeutics Transcript: KOL event
Detalimogene showed 54% complete response at any time in the interim pivotal cohort, with durability still immature. Preclinical polidocanol data support improved delivery and shorter dwell time; clinical efficacy remains under evaluation.
enGene Therapeutics Slides: KOL event
enGene Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 15, 2026.
enGene to Host KOL Webinar on October 15, 2026
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a webin...
enGene Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Detalimogene, a non-viral gene therapy for NMIBC, demonstrates a 54% complete response rate, best-in-class tolerability, and workflow advantages for community practices. With $266 million in cash, pivotal data updates and regulatory filings are planned for late 2026, targeting approval in 2027.
enGene Therapeutics Slides: Corporate presentation
enGene Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 15, 2026.
enGene Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Detalimogene, a non-viral gene therapy for BCG-unresponsive NMIBC, is advancing toward a 2027 U.S. approval, supported by strong interim efficacy and safety data. The therapy is designed for easy adoption in community practices, with a commercial strategy targeting rapid uptake and broad reimbursement.
enGene Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
Detalimogene voraplasmid is advancing toward FDA submission, with pivotal data maturing by year-end and strong interim efficacy and tolerability. Positioned for broad adoption in community urology practices, the product's ease of use and robust safety profile differentiate it, while a surfactant cohort aims to further enhance outcomes.
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for...
enGene Therapeutics Earnings release: Q3 2026
enGene Therapeutics released its Q3 2026 earnings on September 8, 2026, summarizing the period's financial results.
enGene Therapeutics Quarterly report: Q3 2026
enGene Therapeutics has published its Q3 2026 quarterly earnings report on September 8, 2026.